Artificial Intelligence Assessment of Renal Scarring (AIRS Study). Issue 1 (27th January 2022)

• Record Type: Journal Article
• Authors: Chantaduly, Chanon; Troutt, Hayden R.; Perez Reyes, Karla A.; Zuckerman, Jonathan E.; Chang, Peter D.; Lau, Wei Ling
• Is Part Of: Kidney360. Volume 3:Issue 1(2022)
• Page Start: 83
• Page End: 90
• Publication Date: 2022-01-27
• Subjects: clinical nephrology -- artificial intelligence -- convoluted neural networks -- CT imaging -- kidney biopsy -- kidney fibrosis -- machine learning -- renal fibrosis; 616.61
• DOI: 10.34067/KID.0003662021
• Languages: English
• ISSNs: 2641-7650

Abstract

Key Points: In this pilot study, two AI algorithms showed approximately 85% accuracy in predicting kidney fibrosis severity (using kidney biopsies as ground-truth). Machine learning algorithms are a promising noninvasive diagnostic tool to quantify kidney fibrosis from CT scans. Visual Abstract: Abstract : Background: The goal of the Artificial Intelligence in Renal Scarring (AIRS) study is to develop machine learning tools for noninvasive quantification of kidney fibrosis from imaging scans. Methods: We conducted a retrospective analysis of patients who had one or more abdominal computed tomography (CT) scans within 6 months of a kidney biopsy. The final cohort encompassed 152 CT scans from 92 patients, which included images of 300 native kidneys and 76 transplant kidneys. Two different convolutional neural networks (slice-level and voxel-level classifiers) were tested to differentiate severe versus mild/moderate kidney fibrosis (≥50% versus <50%). Interstitial fibrosis and tubular atrophy scores from kidney biopsy reports were used as ground-truth. Results: The two machine learning models demonstrated similar positive predictive value (0.886 versus 0.935) and accuracy (0.831 versus 0.879). Conclusions: In summary, machine learning algorithms are a promising noninvasive diagnostic tool to quantify kidney fibrosis from CT scans. The clinical utility of these prediction tools, in terms of avoiding renal biopsy and associated bleeding risks in patients with severe fibrosis, remains to be validated in prospective clinical trials.